 <h1>Belimumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of belimumab include:</b> infection, serious infection, hypersensitivity reaction, mental disorders, and nausea. <b>Other side effects include:</b> bronchitis, leukopenia, depression, insomnia, and nasopharyngitis.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to belimumab: powder for solution, solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, belimumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking belimumab:</p><p>
<i>More common</i>
</p><ul>
<li>Bladder pain</li>
<li>bleeding, blistering, burning, coldness, skin discoloration, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>bloody or cloudy urine</li>
<li>body aches or pain</li>
<li>chest pain or tightness</li>
<li>chills</li>
<li>cough</li>
<li>cough producing mucus</li>
<li>diarrhea</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty with breathing or swallowing</li>
<li>dizziness</li>
<li>ear congestion</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>headache, severe and throbbing</li>
<li>hives, skin rash</li>
<li>itching, pain, redness, swelling, tenderness, or warmth of the skin</li>
<li>joint pain</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>muscle aches and pains</li>
<li>nausea</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>swelling of the eyes, face, or inside of the nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
<li>sweating</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>discouragement</li>
<li>fast heartbeat</li>
<li>feeling sad or empty</li>
<li>hoarseness</li>
<li>irritability</li>
<li>loss of interest or pleasure</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>tender, swollen glands in the neck</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
<li>unusual bleeding or bruising</li>
<li>voice changes</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of belimumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Arm or leg pain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Stomach pain</li>
</ul><p>
<!-- end powder for solution, solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to belimumab: intravenous powder for injection, subcutaneous solution</i></p><h3>General</h3><p>The most common adverse events were infections, headache, infusion reactions, arthralgia, nausea, hypersensitivity reactions, diarrhea, urinary tract infection, and pyrexia.<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infections (non-opportunistic) (70%)</p>
<p><b>Common</b> (1% to 10%): Serious infections, pharyngitis, cystitis, gastroenteritis viral, anti-belimumab antibodies</p>
<p><b>Uncommon</b> (0.1% to 1%): Infections resulting in death</p>
<p><b>Frequency not reported</b>: Progressive multifocal leukoencephalopathy<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Infusion-related reactions (17%), hypersensitivity reactions (13%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Serious infusion reaction, anaphylaxis, angioedema</p>
<p><b>Rare</b> (less than 0.1%): Delayed-type non-acute hypersensitivity reactions</p>
<p><b>Postmarketing reports</b>: Fatal anaphylaxis<sup>[Ref]</sup></p><p>-Hypersensitivity reaction covers a group of terms, including anaphylaxis, and symptoms including hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea.  </p>
<p>-Infusion-related reaction covers a group of terms including bradycardia, myalgia, headache, rash, urticaria, pyrexia, hypotension, hypertension, dizziness, and arthralgia.  </p>
<p>-Delayed-type, non- acute hypersensitivity reactions included rash, nausea, fatigue, myalgia, headache, and facial edema.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (21%)</p>
<p><b>Common</b> (1% to 10%): Migraine, fatigue<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (18%) </p>
<p><b>Common</b> (1% to 10%): Nasopharyngitis, bronchitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (16%)</p>
<p><b>Common</b> (1% to 10%): Pain in extremity<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (15%), diarrhea (12%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection</p>
<p><b>Common</b> (1% to 10%): Cystitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (10%) </p>
<p><b>Common</b> (1% to 10%): Fatigue</p>
<p><b>Uncommon</b> (0.1% to 1%): Death<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia, depression, anxiety</p>
<p><b>Uncommon</b> (0.1% to 1%): Serious depression, suicide<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Leukopenia<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Malignancies<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Rash, urticaria<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. BENLYSTA (belimumab)." GlaxoSmithKline, Research Triangle Park, NC. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about belimumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>41 Reviews</li>
<li>Drug class: selective immunosuppressants</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Belimumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Benlysta</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Lupus Nephritis</li>
<li>Systemic Lupus Erythematosus</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to belimumab: intravenous powder for injection, subcutaneous solution</i></p><h3>General</h3><p>The most common adverse events were infections, headache, infusion reactions, arthralgia, nausea, hypersensitivity reactions, diarrhea, urinary tract infection, and pyrexia.<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infections (non-opportunistic) (70%)</p><p><b>Common</b> (1% to 10%): Serious infections, pharyngitis, cystitis, gastroenteritis viral, anti-belimumab antibodies</p><p><b>Uncommon</b> (0.1% to 1%): Infections resulting in death</p><p><b>Frequency not reported</b>: Progressive multifocal leukoencephalopathy<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Infusion-related reactions (17%), hypersensitivity reactions (13%)</p><p><b>Uncommon</b> (0.1% to 1%): Serious infusion reaction, anaphylaxis, angioedema</p><p><b>Rare</b> (less than 0.1%): Delayed-type non-acute hypersensitivity reactions</p><p><b>Postmarketing reports</b>: Fatal anaphylaxis<sup>[Ref]</sup></p><p>-Hypersensitivity reaction covers a group of terms, including anaphylaxis, and symptoms including hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea.  </p><p>-Infusion-related reaction covers a group of terms including bradycardia, myalgia, headache, rash, urticaria, pyrexia, hypotension, hypertension, dizziness, and arthralgia.  </p><p>-Delayed-type, non- acute hypersensitivity reactions included rash, nausea, fatigue, myalgia, headache, and facial edema.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (21%)</p><p><b>Common</b> (1% to 10%): Migraine, fatigue<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (18%) </p><p><b>Common</b> (1% to 10%): Nasopharyngitis, bronchitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (16%)</p><p><b>Common</b> (1% to 10%): Pain in extremity<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (15%), diarrhea (12%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection</p><p><b>Common</b> (1% to 10%): Cystitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (10%) </p><p><b>Common</b> (1% to 10%): Fatigue</p><p><b>Uncommon</b> (0.1% to 1%): Death<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia, depression, anxiety</p><p><b>Uncommon</b> (0.1% to 1%): Serious depression, suicide<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Leukopenia<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Malignancies<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Rash, urticaria<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. BENLYSTA (belimumab)." GlaxoSmithKline, Research Triangle Park, NC. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about belimumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>41 Reviews</li>
<li>Drug class: selective immunosuppressants</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Belimumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Lupus Nephritis</li>
<li>Systemic Lupus Erythematosus</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>